GlassScriptPhysician profile
Elizabeth Mathew
NPI 1750668158
$2,507.59
in general payments reported to CMS, 2019-2025
25 companies · $41.59 in 2025
The $41.59 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $554 · 2023: $827 · 2024: $478 · 2025: $41.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $723.97 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $400.63 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Abbvie INC. | $305.69 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $205.06 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $145.67 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.51 | 2021-2023 | Jardiance, Tradjenta, Synjardy |
| Mylan Specialty L.P. | $71.80 | 2021-2022 | |
| Astellas Pharma US INC | $52.63 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $51.03 | 2023-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $48.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $45.64 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $44.36 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Medtronic, INC. | $40.58 | 2023-2025 | Venaseal, Corevalve Evolut R |
| Inspire Medical Systems, INC. | $40.24 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $38.88 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $33.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.95 | 2023 | |
| Corcept Therapeutics | $22.58 | 2024 | Korlym |
| Becton, Dickinson and Company | $21.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.22 | 2021 | |
| Merck Sharp & Dohme LLC | $19.80 | 2023 | Verquvo, Steglujan, Steglatro |
| Intuity Medical INC | $19.30 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Eisai INC. | $18.49 | 2021 | |
| Boston Scientific Corporation | $18.33 | 2025 | General - Pain Management |
| Xeris Pharmaceuticals, INC. | $16.88 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.